ENDO: Testosterone-Replacement Noninferior to Placebo for Cardiovascular Events
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, June 22, 2023 -- For men with preexisting cardiovascular disease or a high risk for cardiovascular disease and hypogonadism, testosterone-replacement therapy is noninferior to placebo for the incidence of major adverse cardiac events, according to a study published online June 16 in the New England Journal of Medicine to coincide with the annual meeting of the Endocrine Society, held from June 15 to 18 in Chicago.
A. Michael Lincoff, M.D., from the Cleveland Clinic, and colleagues conducted a multicenter, randomized trial involving 5,246 men aged 45 to 80 years with preexisting cardiovascular disease or a high risk for cardiovascular disease, reported symptoms of hypogonadism, and two fasting testosterone levels of <300 ng/dL. Participants were randomly assigned to receive daily transdermal 1.62 percent testosterone gel or placebo gel.
The researchers found that a primary cardiovascular end point event (first occurrence of any component of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, assessed in a time-to-event analysis) occurred in 7.0 and 7.3 percent of patients in the testosterone and placebo groups, respectively (hazard ratio, 0.96; 95 percent confidence interval, 0.78 to 1.17). In sensitivity analyses in which data on events were censored at various times after discontinuation of testosterone or placebo, the findings were similar. The two groups had a similar incidence of secondary end point events or of each of the events of the composite primary cardiovascular end point.
"Our findings regarding the cardiovascular safety of testosterone may facilitate a more informed consideration of the potential benefits and risks of testosterone therapy among middle-aged and older men with hypogonadism," the authors write.
The study was funded by AbbVie, Acerus Pharmaceuticals, Endo Pharmaceuticals, and Upsher-Smith Laboratories. Several authors disclosed financial ties to industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
AI-Informed Health App Aids Diabetes Outcomes
WEDNSDAY, May 15, 2024 -- Use of an artificial intelligence (AI)-informed health app aids diabetes outcomes and cuts atherosclerotic cardiovascular disease (ASCVD) risk, according...
Fat-Enlarged Axillary Nodes on Mammogram May Indicate Higher CVD Risk
TUESDAY, May 14, 2024 -- Fat-enlarged axillary nodes on screening mammograms can predict the risk for cardiovascular disease (CVD), according to a study presented at the annual...
Adding Cardiovascular Biomarkers to Established Risk Factors Increases Risk Prediction
MONDAY, May 13, 2024 -- The addition of cardiovascular biomarkers to established risk factors leads to a small improvement in risk prediction of cardiovascular disease, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.